Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00387764
Registration number
NCT00387764
Ethics application status
Date submitted
12/10/2006
Date registered
13/10/2006
Date last updated
14/01/2014
Titles & IDs
Public title
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
Query!
Scientific title
An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192
Query!
Secondary ID [1]
0
0
VEG107769
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Renal Cell
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - pazopanib
Experimental: pazopanib arm - This was a single arm study, therefore no control arm.
Treatment: Drugs: pazopanib
800 mg daily dosing continously until progression
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
Query!
Assessment method [1]
0
0
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations.
Query!
Timepoint [1]
0
0
From Baseline to Follow-up (up to 6.230 years)
Query!
Primary outcome [2]
0
0
Number of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Severity, Per National Cancer Institute (NCI) Common Terminology Criteria in Adverse Events (CTCAE)
Query!
Assessment method [2]
0
0
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations. Adverse events were graded for severity according to the NCI CTCAE, version 3.0: Grade 1, mild; Grade 2, moderate; Grade 3 (G3), severe; Grade 4 (G4), life-threatening or disabling; Grade 5, death.
Query!
Timepoint [2]
0
0
From Baseline to Follow-up (up to 6.230 years)
Query!
Primary outcome [3]
0
0
Number of Participants With Adverse Events Related to Investigational Product
Query!
Assessment method [3]
0
0
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The investigator assessed relatedness between the AE and the investigational product.
Query!
Timepoint [3]
0
0
From Baseline to Follow-up (up to 6.230 years)
Query!
Primary outcome [4]
0
0
Median Time on Investigational Product
Query!
Assessment method [4]
0
0
The time on investigational product (including dose interruptions) is defined as the difference between the date of the last dose of investigational product and the date of the first dose of investigational product plus one.
Query!
Timepoint [4]
0
0
From Baseline to investigational product discontinuation (up to 6.230 years)
Query!
Primary outcome [5]
0
0
Number of Participants With the Indicated Worst-case Toxicity Grade Increase From Baseline for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline
Query!
Assessment method [5]
0
0
Clinical chemistry parameters were summarized according to NCI CTCAE, version 4.0: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death. Data are presented for only those parameters for which an increase from Baseline occurred. Clinical chemistry parameters included: alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin (TB), calcium (hypercalcemia and hypocalcemia), creatinine, glucose (hyperglycemia and hypoglycemia), potassium (hyperkalemia and hypokalemia), magnesium (hypermagnesemia and hypomagnesemia), sodium (hypernatremia and hyponatremia), and phosphate.
Query!
Timepoint [5]
0
0
From Baseline to investigational product discontinuation (up to 6.230 years)
Query!
Primary outcome [6]
0
0
Number of Participants With the Indicated Worst-case Grade Increase From Baseline for the Indicated Hematology Parameters at Any Time Post-Baseline
Query!
Assessment method [6]
0
0
Hematology parameters were summarized according to NIH CTCAE, version 4.0. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death. Data are presented for only those parameters for which an increase from Baseline occurred. Hematology parameters included: hemoglobin (anemia), lymphocytes (lymphocytopenia), neutrophils (neutropenia), platelets (thrombocytopenia), white blood cells (WBC \[leukopenia\]), and prothrombin time international normalized ratio (PT \[INR\]). Participants with missing Baseline grades are assumed to have a Baseline grade of 0.
Query!
Timepoint [6]
0
0
From Baseline to investigational product discontinuation (up to 6.230 years)
Query!
Primary outcome [7]
0
0
Number of Participants With the Indicated Shift From Baseline in Blood Pressure at Any Time Post-Baseline
Query!
Assessment method [7]
0
0
Blood pressure measurements included systolic blood pressure (SBP, millimeters of mercury \[mmHg\]) and diastolic BP (DBP). The number of participants with a post-Baseline shift from Baseline in blood pressure (\<90 mmHg, 90 to 139 mmHg, 140 to 169 mmHg, \>=170 mmHg) was assessed.
Query!
Timepoint [7]
0
0
From Baseline to investigational product discontinuation (up to 6.230 years)
Query!
Primary outcome [8]
0
0
Number of Participants With the Indicated Shift in Heart Rate From Baseline at Any Time Post-Baseline
Query!
Assessment method [8]
0
0
Heart rate is the measure of heart beats per minute (bpm). The number of participants with a post-Baseline shift from Baseline in heart rate of \<44 bpm, 44 to 100 bpm, 101 to 120 bpm, and \>120 bpm was assessed.
Query!
Timepoint [8]
0
0
From Baseline to investigational product discontinuation (up to 6.230 years)
Query!
Primary outcome [9]
0
0
Number of Participants With a Change From Baseline to the Indicated Worst-case Post-Baseline Bazett's Heart Rate-corrected QT Interval (QTc) Value
Query!
Assessment method [9]
0
0
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. A lengthened QT interval can be a biomarker for ventricular tachyarrhythmias. The QT interval corrected for heart rate using Bazett's formula (QTcB) was calculated; the faster the heart rate, the shorter the QT interval. Electrocardiogram values (Bazett's QTc value) were summarized using the following reference ranges: \<450, 450 to 479, 480 to 499, 500 to 549, and \>550 milliseconds.
Query!
Timepoint [9]
0
0
From Baseline to investigational product discontinuation (up to 6.230 years)
Query!
Secondary outcome [1]
0
0
Number of Participants With a Complete Response (CR) or Partial Response (PR)
Query!
Assessment method [1]
0
0
Overall tumor response is defined as the number of participants achieving either a confirmed complete or partial tumor response per Response Evaluation Criteria in Solid Tumors (RECIST). RECIST guidelines were used to evaluate the measurability of tumor lesions, to determine target and non-target lesions at Baseline, and to evaluate tumor response or disease progression after study start. CR is defined as the disappearance of all target and non-target lesions, and PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions, taking as a reference the Baseline sum LD, as assessed by the investigator. Confirmation of a CR/PR required a subsequent assessment of the same response or better at least 28 days after the original response.
Query!
Timepoint [1]
0
0
From Baseline to Week 24/investigational product discontinuation (up to 3.460 years)
Query!
Secondary outcome [2]
0
0
Number of Participants With a Response of Confirmed CR+PR+6-month Stable Disease (SD)
Query!
Assessment method [2]
0
0
The number of participants who achieved either a CR, a PR, or a best response of SD that occurred at least 6 months after screening per RECIST criteria was assessed. CR is defined as the disappearance of all target and non-target lesions; PR is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD; and SD is defined as neither sufficient shrinkage in target lesions to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started and the persistence of one or more non-target lesion(s), as assessed by the investigator. Confirmation of a CR/PR required a subsequent assessment of the same response or better at least 28 days after the original response. A confirmed response of SD required that the SD assessment occurred no earlier than 12 weeks after the screening scans.
Query!
Timepoint [2]
0
0
From the Baseline to Week 24/investigational product discontinuation (up to 1.65 years)
Query!
Secondary outcome [3]
0
0
Number of Participants With the Indicated Best Overall Response
Query!
Assessment method [3]
0
0
The best overall response is defined as the best response recorded from the start of the treatment until disease progression (PD)/recurrence. Per RECIST: CR, the disappearance of all target and non-target lesions; PR, at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD; SD, neither sufficient shrinkage in target lesions to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started and the persistence of one or more non-target lesion(s); PD, at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum of the LD recorded since the treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions. Unknown/not evaluable is used for those participants who cannot be classified as achieving CR, PR, SD, or PD.
Query!
Timepoint [3]
0
0
From the Baseline to Week 24/investigational product discontinuation (up to 3.460 years)
Query!
Secondary outcome [4]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [4]
0
0
PFS is defined as the interval between the date of the first dose of study medication and the date of disease progression as defined by the investigator or death due to any cause. RECIST was used to evaluate the measurability of tumor lesions, to determine target and non-target lesions at Baseline, and to evaluate tumor response or disease progression after study start. Per RECIST, PD is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum of the LD recorded since the treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions. Participants who did not have disease progression or did not die were censored at the follow-up visit as either follow-up ended or follow-up ongoing. Participants who received non-study anti-cancer therapies before disease progression were treated as censored.
Query!
Timepoint [4]
0
0
From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to 3.460 years)
Query!
Secondary outcome [5]
0
0
Overall Survival (OS)
Query!
Assessment method [5]
0
0
OS is defined as the interval between the date of the first dose of study medication to the date of death due to any cause. For participants who did not die, time to death was censored at the time of last contact. The last date of contact was defined as the maximum date of any visit date or the survival follow-up date.
Query!
Timepoint [5]
0
0
From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to 3.460 years)
Query!
Secondary outcome [6]
0
0
Percentage of Participants Who Survived Until Month 12
Query!
Assessment method [6]
0
0
For participants who did not die, time to death was censored at the time of last contact. The last date of contact was defined as the maximum date of any visit date or the survival follow-up date.
Query!
Timepoint [6]
0
0
From the first dose of study medication to Month 12
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* Progressed from VEG105192 study treatment
* Patient's VEG105192 was placebo
* Baseline has good organ function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* No brain metastasis
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
80
Query!
Recruitment in Australia
Recruitment state(s)
NSW,TAS,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Waratah
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Hobart
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [2]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Buenos Aires
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Córdova
Query!
Country [3]
0
0
Argentina
Query!
State/province [3]
0
0
Santa Fe
Query!
Country [4]
0
0
Argentina
Query!
State/province [4]
0
0
Quilmes
Query!
Country [5]
0
0
Argentina
Query!
State/province [5]
0
0
Tucuman
Query!
Country [6]
0
0
Austria
Query!
State/province [6]
0
0
Salzburg
Query!
Country [7]
0
0
Austria
Query!
State/province [7]
0
0
Vienna
Query!
Country [8]
0
0
Brazil
Query!
State/province [8]
0
0
Minas Gerais
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
Rio Grande Do Sul
Query!
Country [10]
0
0
Chile
Query!
State/province [10]
0
0
Región Metro De Santiago
Query!
Country [11]
0
0
Chile
Query!
State/province [11]
0
0
Valparaíso
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Beijing
Query!
Country [13]
0
0
Czech Republic
Query!
State/province [13]
0
0
Brno
Query!
Country [14]
0
0
Czech Republic
Query!
State/province [14]
0
0
Chomutov
Query!
Country [15]
0
0
Czech Republic
Query!
State/province [15]
0
0
Praha 2
Query!
Country [16]
0
0
Estonia
Query!
State/province [16]
0
0
Tartu
Query!
Country [17]
0
0
Italy
Query!
State/province [17]
0
0
Lazio
Query!
Country [18]
0
0
Korea, Republic of
Query!
State/province [18]
0
0
Seoul
Query!
Country [19]
0
0
Korea, Republic of
Query!
State/province [19]
0
0
songpa-gu, Seoul
Query!
Country [20]
0
0
Latvia
Query!
State/province [20]
0
0
Riga
Query!
Country [21]
0
0
Lithuania
Query!
State/province [21]
0
0
Kaunas
Query!
Country [22]
0
0
Lithuania
Query!
State/province [22]
0
0
Vilnius
Query!
Country [23]
0
0
New Zealand
Query!
State/province [23]
0
0
Christchurch
Query!
Country [24]
0
0
New Zealand
Query!
State/province [24]
0
0
Wellington
Query!
Country [25]
0
0
Pakistan
Query!
State/province [25]
0
0
Karachi
Query!
Country [26]
0
0
Pakistan
Query!
State/province [26]
0
0
Lahore
Query!
Country [27]
0
0
Poland
Query!
State/province [27]
0
0
Gdansk
Query!
Country [28]
0
0
Poland
Query!
State/province [28]
0
0
Krakow
Query!
Country [29]
0
0
Poland
Query!
State/province [29]
0
0
Kraków
Query!
Country [30]
0
0
Poland
Query!
State/province [30]
0
0
Olsztyn
Query!
Country [31]
0
0
Russian Federation
Query!
State/province [31]
0
0
Chelyabinsk
Query!
Country [32]
0
0
Russian Federation
Query!
State/province [32]
0
0
Kazan
Query!
Country [33]
0
0
Russian Federation
Query!
State/province [33]
0
0
Moscow
Query!
Country [34]
0
0
Russian Federation
Query!
State/province [34]
0
0
Omsk
Query!
Country [35]
0
0
Russian Federation
Query!
State/province [35]
0
0
Samara
Query!
Country [36]
0
0
Russian Federation
Query!
State/province [36]
0
0
St. Petersburg
Query!
Country [37]
0
0
Russian Federation
Query!
State/province [37]
0
0
Voronezh
Query!
Country [38]
0
0
Russian Federation
Query!
State/province [38]
0
0
Yaroslavl
Query!
Country [39]
0
0
Slovakia
Query!
State/province [39]
0
0
Bratislava
Query!
Country [40]
0
0
Tunisia
Query!
State/province [40]
0
0
Sfax
Query!
Country [41]
0
0
Tunisia
Query!
State/province [41]
0
0
Sousse
Query!
Country [42]
0
0
Tunisia
Query!
State/province [42]
0
0
Tunis
Query!
Country [43]
0
0
Ukraine
Query!
State/province [43]
0
0
Donetsk
Query!
Country [44]
0
0
Ukraine
Query!
State/province [44]
0
0
Kharkiv
Query!
Country [45]
0
0
Ukraine
Query!
State/province [45]
0
0
Kyiv
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Bebington, Wirral
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
Belfast, Northern Ireland
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an open-label, international, multi-center study designed to provide access to pazopanib for subjects who have been enrolled in the Phase III renal cell carcinoma study (VEG105192) and have progressed on placebo. Subjects will receive 800 mg pazopanib once daily. The study treatment will continue until subjects experience disease progression, unacceptable toxicity, withdrawal of consent, or death. The primary objective of the study is to evaluate the safety and tolerability of pazopanib for the treatment of renal cell carcinoma. The secondary objectives of the study are to assess response rate (defined as complete response or partial response), progression-free survival, and overall survival. Response rates will be collected per investigator assessment (no central review). Subjects will have a CT/MRI scan every 6 weeks until week 24 and every 12 weeks thereafter.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00387764
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00387764
Download to PDF